March 20, 2018 / 4:15 PM / 8 months ago

BRIEF-Novo Nordisk's ‍Semaglutide Data Demonstrates Significant Weight Loss​

March 20 (Reuters) - Novo Nordisk:

* ‍SEMAGLUTIDE INJECTION PHASE 2 DATA PRESENTED AT ENDOCRINE SOCIETY’S ANNUAL MEETING IN CHICAGO DEMONSTRATED SIGNIFICANT WEIGHT LOSS IN ADULTS WITH OBESITY​

* ‍ADULTS WITH OBESITY TREATED WITH SEMAGLUTIDE 0.4 MG ADMINISTERED ONCE-DAILY VIA SUBCUTANEOUS INJECTIONS LOST UP TO 13.8 PCT OF THEIR BODY WEIGHT AFTER 52 WEEKS

* THAT WAS SIGNIFICANTLY MORE THAN THOSE TREATED WITH PLACEBO WHO LOST 2.3 PCT OF THEIR BODY WEIGHT

* 83 PCT OF PEOPLE TREATED WITH SEMAGLUTIDE 0.4 MG LOST AT LEAST 5 PCT OF THEIR BODY WEIGHT AND 65 PCT LOST AT LEAST 10 PCT

* ‍PLANS TO START STEP PHASE 3 CLINICAL DEVELOPMENT PROGRAMME LATER THIS YEAR​ Further company coverage: (Copenhagen newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below